Ascletis announces asc47, a muscle-preserving weight loss drug candidate for treatment of obesity, in combination with semaglutide, demonstrated superior weight loss to semaglutide monotherapy in a preclinical model

In a head-to-head diet-induced obese (dio) mouse study, asc47 low dose combination 1 (asc47, 3 mg/kg, subcutaneous ( sq ) , once every four weeks plus semaglutide, 30 nmol/kg, sq, once daily) ,  demonstrated superior weight loss compared to semaglutide monotherapy (30 nmol/kg, sq, once daily), showing an average total body weight reduction of 36.2% compared to 23.1%, a 56.7% greater reduction in body weight compared to semaglutide monotherapy. human equivalent dose of asc47 low dose 1 (3 mg/kg, sq, once every four weeks) in mice is estimated to be approximately 20 mg based on the body surface area conversion.
ASC Ratings Summary
ASC Quant Ranking